Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or SLL, as well as against bendamustine plus rituximab in treatment-naïve CLL or SLL patients.

Latest news

More from news
Approximately 158 fully matching, plus 423 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 5 fully matching, plus 59 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...